Purpose of Review Tobacco use, sex differences, and psychiatric disorders are associated with altered immune function. There are also sex differences in tobacco use and psychiatric disorders. This review summarizes findings from the small, but growing literature examining sex differences in the effects of tobacco use on inflammation and the implications for psychiatric disorders.
Introduction
As one of the leading causes of morbidity and mortality, it is well-known that tobacco smoking contributes to increased risk of cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and cancer [1] . CVD, COPD, and cancer are all characterized by elevated levels of inflammation [2] [3] [4] . Thus, a shared mechanism by which tobacco smoking may contribute to these medical conditions may be through tobacco's effects on inflammation [5, 6] . Indeed, tobacco smoking induces inflammatory markers including C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and activated macrophages [7] [8] [9] [10] [11] .
Numerous studies have also observed sex differences in inflammatory response and immune function [12, 13] as well as in the effects of and ability to quit tobacco smoking [14••] . Therefore, it is plausible that observed sex differences in the prevalence and severity of COPD, CVD, and cancer may be partly attributed to the interaction between sex, tobacco use, and inflammation.
Elevated inflammation and immune dysregulation have been associated with several psychiatric disorders including depression, schizophrenia, and bipolar disorder [15] [16] [17] . There is also evidence for sex differences in psychiatric disorders, with the strongest support for a difference in the prevalence of depression, with females having a higher prevalence than males [18••] . Notably, the smoking rate among adults with psychiatric disorders, such as schizophrenia spectrum, bipolar, and recurring depressive disorders, ranges from 45 to 85%, which is 3 to 4 times the rate of the general population [19] [20] [21] . Therefore, it is possible that inflammation represents a common mechanism that may partially explain the relationship between tobacco smoking and psychiatric disorders and how sex may modulate this relationship. In this review, we discuss the evidence for sex differences in immune responses, tobacco smoking, and psychiatric disorders and how this This article is part of the Topical Collection on Reproductive Psychiatry and Women's Health information might be used to develop more targeted strategies for treating both tobacco dependence and psychiatric disorders ( Fig. 1) . We also discuss the potential paradoxical effects of nicotine (vs. tobacco smoking) on inflammation, as well as the implications for emerging tobacco products, such as electronic cigarettes.
Effects of Tobacco Use and Nicotine on Inflammation
Numerous studies have demonstrated that smokers exhibit elevated levels of inflammation across a variety of markers, relative to non-smokers. Tobacco-induced inflammation is believed to be one of the primary pathways by which tobacco smoking contributes to acute and chronic inflammatory diseases, including CVD, COPD, acute respiratory distress syndrome, and lung cancer [6] . Although this topic has been reviewed in depth elsewhere [8, 22, 23] , CRP, cytokines (e.g., IL-6), markers of oxidative stress (nitric oxide), cell adhesion molecules (e.g., ICAM), and markers associated with vascular inflammation (e.g., MMP-9) have all demonstrated sensitivity to smoking status [7, [24] [25] [26] [27] . Tobacco smoke may also downregulate expression of genes involved with regulation of immune function [9] . Although there is some evidence that smoking burden (e.g., number of cigarettes smoked per day and/or number of years smoked) is positively associated with inflammation [24, 28, 29] , others have found no relationship [27] . Importantly, former smokers exhibit lower levels of inflammation relative to current smokers [27] and reductions in inflammation following smoking cessation have been observed, particularly markers reflecting oxidative stress [28, 30] . While the precise duration for decreased inflammation following cessation remains an important research question, several studies have shown a relationship between time since cessation and reductions in inflammation, with times ranging from 4 months to 20 years [27, 30, 31] . Therefore, the adverse effects of tobacco smoking on inflammation may be reversible.
Despite the adverse effects of tobacco use on inflammation, nicotine alone, the main psychoactive ingredient in cigarettes, may have opposite effects. Nicotine attenuates proinflammatory cytokines interleukin-1β (IL)-1β, IL-6, tumor necrosis factor alpha (TNF)-α [32] and inhibits nuclear factor kappa (NFkB) signaling [33] . Many of nicotine's antiinflammatory properties are attributed to its activation of the α7 nicotinic acetylcholine receptors (nAChRs) [32, 34, 35•] . For instance, activation of α7 nAChRs suppresses abnormal activation of microglia and expression of CD14, ICAM-1, CD40, and TNF-α [36] [37] [38] , and the α7 nAChR antagonist mecamylamine reverses these effects [36] . In addition, nicotine may alter expression of genes involved with immune function, upregulating some genes (e.g., TGF-β1, IL-4, CCR2, CXCR6, IL-1α) and downregulating others (e.g., TNF-α, CCL2, IL-8, IL-10, CXCR4, IRF4) [39, 40] .
The differential effects of nicotine alone compared to combustible tobacco may have important implications for emerging tobacco products. For instance, the use of electronic nicotine delivery systems, or ENDS (e.g., e-cigarettes, vape pens), has dramatically increased, particularly among youth and young adults [41] . ENDS deliver nicotine via a liquid that is heated to form a vapor, and thus, deliver nicotine without combusting tobacco. Because ENDS do not burn tobacco, ENDS are typically perceived as less harmful than conventional cigarettes. Short-term studies have shown that switching to ENDS (from combustible tobacco) may yield reductions in inflammation [42•] ; however, emerging data show that ENDS may cause inflammation similar to, yet distinct from, smoking combustible cigarettes [43, 44] . In general, the magnitude of the effects of ENDS on toxicant exposure is smaller than combustible tobacco, but ENDS still induce inflammation. Interestingly, ENDS aerosol exposure increases cytokine levels, with or without nicotine, suggesting that the chemicals in the aerosol are sufficient to produce proinflammatory effects (for a review, see [42•] ). Other parameters may be important to the inflammatory effects of ENDS including the temperature at which the aerosol is heated, the ingredients used to flavor the aerosol, and the base constituents of e-liquids which are not contained in combustible tobacco (e.g., propylene glycol and vegetable glycerin). When heated, propylene glycol and vegetable glycerin produce carbonyls, including acrolein, formaldehyde, and acetaldehyde, which have adverse effects on lung and cardiovascular function [42•, 45] . Moreover, diacetyl, which is used in flavors such as caramel and butterscotch, and benzaldehyde, which is used in fruit flavorings, have been associated with Fig. 1 Hypothetical model for the interaction between sex, tobacco use, and inflammation. In this review, we propose that the sex differences observed in inflammation (path b) and in tobacco use (path a) may interact to modulate the effect of tobacco use on inflammation. This interaction (shaded box) may have important effects on comorbid conditions associated with inflammation, including psychiatric disorders respiratory disease and cytotoxicity [42•] . To date, there is a paucity of human data on the long-term effects of ENDS use or the effects of ENDS use among never smokers. Consequently, rigorous research designed to identify the effects of ENDS use is needed.
Sex Differences in Tobacco Use and the Effects of Nicotine
Sex differences exist across all phases of tobacco use. Men initiate nicotine use at a younger age and report greater nicotine use than women [46] , yet women escalate use and progress to nicotine use disorder faster than men [47] . Women also have greater difficulty with smoking cessation than men [14] . During acute withdrawal, women report more negative affect [48, 49] and more intense cue-induced craving than men [49, 50] . Women also have a higher risk of developing tobaccorelated morbidity and mortality [51, 52] , including increased incidence of lung cancer-related deaths [53] , increased risk for heart attack [54] , and increased risk for COPD [55] .
A large body of literature suggests that sex differences in the effects of nicotine may contribute to the sex differences described above (for recent reviews, see [56] [57] [58] ). In this section, we provide a brief overview of sex differences in the effects of nicotine. In general, sex differences are first established during early fetal development when sexual differentiation of the brain occurs. If the SRY gene is present on the Y chromosome, testes development and fetal masculinization occurs with a surge of androgen; whereas, in the absence of the SRY gene, there is an excess of estrogen (i.e., estradiol) leading to feminization of the brain [59] . In addition to mediating sexual differentiation of the brain, gonadal hormones (i.e., testosterone, estrogen, progesterone) influence neurotransmission and modulate a variety of behaviors throughout the lifespan [60••] . Thus, sex differences in the effects of nicotine are likely a result of sexual dimorphisms in biology and the influence of gonadal hormones. For example, males and females differ in biological parameters that influence the pharmacokinetics and metabolism of nicotine. Indeed, clinical studies indicate that women metabolize nicotine at a higher rate than men, and ovarian hormones, specifically estrogen, seem to accelerate nicotine metabolism [61, 62] . However, animal studies do not support these findings [63, 64] . Specifically, animal studies have found comparable rates of nicotine metabolism in males and females [63] or faster nicotine metabolism in males compared to females [64] . Species differences, such as social and cultural factors, likely contribute to the inconsistency between human and animal research.
Sex differences and the influence of gonadal hormones are also evident in subjective, cognitive, and physiological responses to nicotine. DeVito and colleagues (2014) assessed the influence of sex and menstrual cycle phase, a common proxy for ovarian hormones, on several measures of nicotine effects, including subjective drug effects, cognition, physiological responses, and symptoms of withdrawal, craving, and affect using an intravenous nicotine paradigm and overnight abstinence in male and female smokers and found that female smokers had diminished subjective effects, but greater physiological responses, to nicotine [65] . Findings also revealed that luteal-phase female smokers (i.e., higher levels of progesterone relative to estrogen) reported diminished subjective nicotine effects and better cognition compared to follicular-phase (i.e., high estrogen, low progesterone) female smokers. These findings are consistent with a series of studies conducted by Perkins demonstrating greater subjective nicotine sensitivity in male smokers [56] . The Perkins studies also showed that female smokers are more sensitive to the non-nicotine conditioned stimuli (or cues) associated with cigarette smoking [56] . Although these are just a few examples of sex differences in nicotine's effects and the potential influence of gonadal hormones, these findings provide insight into the mechanisms underlying sex differences in tobacco use, which, in turn, could have significant effects on smoking-induced inflammation.
Sex Differences in Inflammatory Responses/Immune Regulation
Several studies have demonstrated sex differences in inflammation and immune function [66] [67] [68] [69] . Although this topic has been reviewed in detail elsewhere [70] , we will provide a brief overview here. In response to infection, estrogen tends to increase the immune response whereas testosterone decreases it. However, the type of microbe causing the infection (e.g., viruses vs. bacteria) may influence sex-specific susceptibility to the infection [70] . For example, while males tend to be more susceptible to bacterial infection, females may exhibit greater inflammatory response to viral infection [70] . One of the most consistent findings is that females have higher levels of CRP compared to males [66, 67, 71] , whereas, in response to bacterial infection, males may express higher levels of IL-6 compared to females [72] . Moreover, there may be stronger associations between inflammation, physical activity, and obesity on subjective outcomes (e.g., fatigue) among females compared to males [68] . Stress-induced inflammatory responses also differ between males and females, which may be due in part to the differential effects of testosterone and estrogen on the hypothalamic-pituitary-adrenal (HPA) axis as well as interactions between glucocorticoid receptors and gonadal hormones. In general, females exhibit greater increases in cytokines following acute stress and tend to show decreased immunity in response to chronic stress [73••] .
Despite the wealth of evidence supporting differential immune responses between males and females, research examining the mechanisms for this effect is still emerging. A number of factors may play a role, including hormonal effects, differences in cell responses that are male or female-even prior to the production of sex hormones, and chronic stress [74, 75] . For instance, the X chromosome contains the highest concentration of genes related to immune function and this is believed to play a role in elevated rates of autoimmune disorders among females compared to males [76] . Preclinical studies have also demonstrated important interactions between sex hormones and inflammatory signaling during fetal development [77•] . Moreover, microglia, which are the primary immune cells of the CNS, are sensitive to external factors and have the potential to substantially impact neurodevelopment (for a review, see [78•] ). Interestingly, the number of microglia vary by sex and age such that during fetal development male rats have more microglia than female rats, but the reverse pattern has been observed in adults [79] . Estrogen receptors also play an important role as they are expressed on various immune cells including B cells, CD4 and CD8 T cells, monocytes, and natural killer (NK) cells [80] . In large epidemiological samples, the use of sex hormones (i.e., estrogen) is associated with elevated CRP levels [67, 71] . As noted above, estrogen interacts with nicotine to alter activity of several cytochrome P450 (CYP) enzymes, which may ultimately result in making female lungs more susceptible to tobacco smokeinduced inflammation [81] .
The Intersection of Sex Differences, Tobacco Use, and Inflammation
This is a growing area of research and the few studies that have been conducted have been preclinical (i.e., rodents) or cross-sectional (Table 1) . Nevertheless, there is evidence to suggest that sex differences may play a role in the interaction between nicotine/tobacco use and inflammation. For example, using the spontaneously hypertensive (SH) rat as a model of COPD, Shen and colleagues found that male SH rats exhibited greater inflammatory responses following prolonged exposure to tobacco smoke [85•] . Specifically, male SH rats demonstrated elevated IL-6, TNF-α, and heme oxygenase-1 (HO-1) following tobacco smoke exposure, whereas female SH rats showed no increase. TNF-α can increase the inflammatory response by activating cytokines (including IL-6), suggesting that male SH rats may be more susceptible to tobacco smokeinduced inflammation. HO-1 is a marker of oxidative stress and is expressed as a mechanism to attenuate inflammation. Therefore, it is possible that the elevated HO-1 observed in SH male rats may reflect a more adaptive response to the increased inflammation in response to exposure to tobacco smoke, relative to female rats [85•].
As noted above, the α7 nAChRs are thought to play an important role in the cholinergic anti-inflammatory pathway, suggesting that a deficiency in α7 nAChRs might exacerbate inflammation [86] . Using a mouse model of colitis, Al Sharari and colleagues tested this hypothesis by treating male and female α7 KO mice and wild-type (WT) mice with dextran sodium sulfate (DSS) to induce colitis symptoms and inflammation [82] . In addition, this study evaluated whether pharmacological approaches to enhancing cholinergic function (α7 nAChR agonist, choline, a positive allosteric modulator of α7 nAChR) would attenuate symptoms of colitis and inflammation. An increase in colitis symptoms and TNF-α was observed among male α7 KO mice, but not among female mice. Rather, the female KO mice showed similar disease severity as the female WT mice. However, while the pharmacological interventions attenuated colitis symptoms, there was no effect on TNF-α levels in male or female mice [82] .
In a study comparing patients with COPD, smokers and non-smokers, Faner et al. (2014) tested the effects of smoking on inflammatory markers and changes in expression of genes related to immune function [83] . The authors measured biomarkers of inflammation at baseline and 180 min after smokers smoked two cigarettes following 8 h of abstinence. Although there was no change in any inflammatory marker following smoking or any sex differences before or after smoking, there were sex differences in the leukocyte transcriptome profile. Importantly, the differential expression of genes between baseline and following smoking varied between males and females. Among females, 61 genes were differentially expressed following smoking compared to only 19 genes among males. Of these 61 genes, several related to the immune response (IL18RAP), apoptosis, and cell death (MMP9, ADRB2, TNFSF14) [83] .
There may also be sex differences across populations that impact the effect of tobacco smoke on inflammation. For example, Moscovis and colleagues evaluated peripheral blood mononuclear cells (PBMCs) from a sample of Indigenous Australians to compare those with a genetic profile indicating high risk for inflammatory responses versus those with low risk [84] . In addition, they evaluated whether these differences varied between males and females. To induce inflammation, PBMCs were treated with one of seven conditions: lipopolysaccharide (LPS), IFN-γ, cigarette smoke extract (CSE), LPS + IFN-γ, LPS + CSE, IFN-γ + CSE, or LPS + IFN-γ + CSE. Although there were no overall differences between the high-and low-risk genetic profile, there were interactions with sex. When all three inflammation conditions were combined (LPS + IFN-γ + CSE), males tended to show a reduction in cytokine response (IL-6, TNF-α, IL-1β) relative to females, irrespective of genetic profile. However, among females, those in the high-risk group showed a reduced antiinflammatory (IL-10) response compared to those in the low-risk group [84] . Although this effect was only observed when CSE was combined with LPS and IFN-γ, low IL-10 is often associated with elevated levels of pro-inflammatory cytokines which may ultimately increase overall immune dysregulation [87] . At T0, sex differences in the leukocyte transcriptome were observed There were also sex differences in changes in expression from T0 to T180
Males
The COPD-related signature included upregulation of genes associated with immune function and cellular locomotion; few genes were associated with smoking specifically Male SH rat has more robust inflammatory response compared to female SH and WKY rats
The increased HO-1 expression following TS, suggests a compensatory response to attenuate inflammation
Although the studies described above suggest that there may be important interactions between sex and the effects of tobacco smoke on inflammation, some have found that sex does not modulate the effect of tobacco use on inflammation [25] or changes in inflammation following cessation [29] . It is also difficult to determine the association between sex, inflammation, and tobacco use because many studies do not report whether inflammatory markers differed by sex [25, 28, 31] or sample sizes are too sample to evaluate this question [30] . Moreover, there is very little evidence regarding the mechanism by which this interaction occurs. Only one study that we know of evaluated the association between testosterone and cigarette smoke-induced inflammation as a function of sex [84] . No correlations were observed among males, but among females, testosterone was positively correlated with IL-1β, IL-6, IL-8, and TNF-α. However, as previously described, there may be important interactions between sex hormones (particularly estrogen) and nicotine.
What Is the Role of Sex Differences, Tobacco Use, and Inflammation in Psychiatric Disorders?
In the preceding sections, we reviewed evidence for sex differences in tobacco use and in inflammation/immune responses as well as the effects of tobacco use on inflammation/immune responses (pathways a, b, and c in Fig. 1) . In this section, we will review some of the recent literature supporting the notion that the interactions among these three factors (shaded box in Fig. 1 ) play a role in the incidence and treatment of psychiatric disorders. For example, numerous studies have documented higher rates of major depressive disorder (MDD) among females, compared to males-an effect that is observed across cultures [88, 89] . There is also some evidence that bipolar disorder may be more common among females than males, though this may vary by type (bipolar type 1 vs. type 2) [90] and has not been found in all studies [91] . The manifestation and clinical course of the disorder may exhibit more important sex differences than prevalence alone (e.g., females may exhibit more depressive features than males) [92] . Lastly, sex differences have been observed in schizophrenia, with a higher prevalence among males at younger ages, whereas the prevalence may be higher among females at older ages [93] . However, a recent study of global prevalence found no sex difference in the prevalence of schizophrenia at any age [94] .
Importantly, rates of tobacco use are higher among individuals with psychiatric disorders. Nearly 43% of persons with MDD are smokers [95, 96] , and those with serious mental illness (SMI), such as schizophrenia spectrum, bipolar, and recurring depressive disorders smoke at rates 3 to 4 times those of the general population [19] [20] [21] . Smoking increases risk of first incidence, severity, and recurrence of MDD [97] [98] [99] [100] and heavier smokers are at higher risk of depression [95, 101] . In addition, tobacco use is associated with firstepisode psychosis [102] and those with a psychotic disorder are more nicotine dependent [103] . Moreover, higher levels of inflammation and/or immune dysregulation have been observed in MDD, bipolar disorder, and schizophrenia [15, 104] . Specifically, IL-6, CRP, TNF-α, and MCP-1/CCL2 have been proposed as biomarkers of depression [15, 105, 106] ; IL-6, TNF-α, IL-1β, and IL-1RA may represent immune-related biomarkers in schizophrenia [107] ; and IL-6, TNF-α, IL-2, and IL-8/CXCL8 have been identified as [8, 22, 23] b Marker associated with sex differences [70, 80] potential biomarkers of bipolar disorder. As shown in Table 2 , there is substantial overlap in the markers of inflammation that have been associated with sex differences, tobacco use, and psychiatric disorders. Despite this connection, few studies have explicitly examined this interaction. However, depressed smokers exhibit elevated levels of IL-6, CRP, and TNF-α compared to non-depressed smokers [108] and recent reviews have proposed inflammation as a potential mechanism to explain the relationship between tobacco use and depression [109, 110] . Based on evidence for sex differences in immune response, we suggest that this is an important factor to consider and should be the focus of future research.
Conclusions and Future Directions
Taken together, the relationship between sex, tobacco use, inflammation, and psychiatric disorders are complex. Nicotine and tobacco use have paradoxical effects, with tobacco smoking leading to an immunosuppressant state [8, 22] and nicotine having anti-inflammatory effects [32, 33] . Sex differences in tobacco use and the effects of nicotine may also influence these effects, as male smokers typically smoke more than female smokers. However, female smokers seem to metabolize nicotine faster [61, 62] , have more difficulty with smoking cessation [14••] , and have greater risk for smokingrelated diseases than male smokers [51, 52] . In general, women have higher levels of inflammation and higher rates of autoimmune diseases [12, 13] , which could contribute to the finding that women have higher rates of smoking-related inflammatory disease, including CVD, COPD, and lung cancer. Interestingly, research indicates that estrogen has antiinflammatory effects; however, sex differences seem to supersede the effects of hormones alone in vivo. When sex, smoking, and inflammation are examined together, the limited number of studies indicates that there could be differential effects, but findings differ across studies. These interactions may also identify novel treatment targets. For instance, pharmacological treatments to attenuate inflammation have been proposed as potential treatments for depression [111] . While these therapeutics may not have direct effects on smoking behavior, it is plausible that they may ultimately reduce smoking behavior by ameliorating depressive symptoms, which are well-known risk factors for smoking relapse [112] . Based on the evidence presented above, it may also be possible that individuals who are more susceptible to immune dysregulation and depression (i.e., females) may be more likely to benefit from anti-inflammatory medications for smoking cessation. Future studies examining the relationship between sex, smoking, and inflammation are needed, especially given that there seems to be a link between smoking, inflammation, and psychiatric disorders with women showing higher rates of MDD and bipolar disorder, higher levels inflammation, and higher risk of developing smokingrelated morbidity and mortality.
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